Pivot Bio secured $70 million in a Series B funding round led by Breakthrough Energy Ventures, and included Singapore-headquartered investment company Temasek. The company plans to use the funds to strengthen Pivot Bio's 2019 commercial launch of the first and only nitrogen-producing microbes for U.S.